Serious breathing difficulties, called acute respiratory distress, was the initial clinical manifestation of myasthenia gravis (MG) in a 41-year-old woman, who was described in a recent case study. The woman went to the emergency room with severe breathing problems, progressive shortness of breath, coughing, and difficulty swallowing. She was…
The volume of the extraocular muscles controlling eye movements is decreased in Chinese patients with myasthenia gravis (MG), particularly in those with ophthalmoparesis, or limited eye movement, a study found. Long disease duration was also associated with decreased extraocular muscle volume, but only in patients with ophthalmoparesis. A reduction…
Rituximab effectively treated most myasthenia gravis (MG) patients who were positive for antibodies against muscle-specific tyrosine kinase (MuSK), a small study shows. The therapy eased MG symptoms and led to gains in measures of clinical severity. It also enabled patients to reduce or stop taking other medications,…
More than a quarter of patients with generalized myasthenia gravis (gMG) spend more than a year waiting for an accurate diagnosis, according to a survey-based study conducted across five European countries. Study findings also suggested that patients who waited more than one year to be diagnosed might have…
Kyverna Therapeutics’ experimental cell therapy, KYV-101, has been granted regenerative medicine advanced therapy (RMAT) status by the U.S. Food and Drug Administration (FDA) for treating progressive myasthenia gravis (MG). RMAT designation is intended to expedite the development and FDA review of experimental regenerative treatments that treat, modify, reverse,…
Patients with generalized myasthenia gravis (gMG) with mild pre-surgery muscle weakness had more favorable outcomes after a thymectomy, which involves the surgical removal of the thymus gland, than those with moderate or severe muscle weakness, a study finds. In their study, “Pre-thymectomy disease severity predicts outcome in…
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept to treat generalized myasthenia gravis (gMG), according to a company press release, This Phase 3 clinical trial (NCT06456580) is a global, multi-center, randomized, double-blind, placebo-controlled study in which…
An under-the-skin, or subcutaneous, injectable form of efgartigimod alfa has been approved in China to treat adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor. The therapy was approved as an add-on to standard gMG treatment. This subcutaneous formulation of efgartigimod (efgartigimod…
Get regular updates to your inbox.